广西前三季度药品出口额创新高

Core Insights - Guangxi's pharmaceutical exports have shown significant growth, with a 27.23% year-on-year increase in the first three quarters, reaching 869 million yuan, following a 12.29% growth last year [1] - The region has optimized regulatory services and enhanced international competitiveness, leading to a rise in the number of pharmaceutical companies and products obtaining export certifications [1] - The recognition of the quality of "Made in Guangxi" pharmaceuticals in international markets has contributed to this growth [1] Group 1: Export Growth and Achievements - In the first three quarters, 22 pharmaceutical companies in Guangxi obtained 88 export sales certificates, marking increases of 37.5% and 66.04% respectively [1] - Eight companies received EU raw material drug export certifications for 21 products, with growth rates of 300% and 600% [1] - Guilin South Pharmaceutical Co. and Nanning Yinchuan Meishi Pharmaceutical Co. each surpassed 100 million yuan in annual exports, with Guilin South's anti-malarial drug revenue reaching 424 million yuan [1] Group 2: Product Diversification and Market Expansion - There is a trend towards high-end products, with traditional exports like anti-malarial and raw materials being complemented by traditional Chinese medicine and high-value products [2] - The number of traditional Chinese medicine export varieties increased by 35%, with products entering new markets such as Peru, Singapore, and Malaysia [2] - Guangxi has expanded cooperation with ASEAN countries through various initiatives, including hosting the China-ASEAN Pharmaceutical Cooperation Development Forum and establishing research bases [2]